Jasper Therapeutics, Inc. (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...
Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...
Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...
Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...
Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecules fo...
Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that i...
Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through i...
HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license...
Harvard Bioscience, Inc. will present its latest product innovations at the Society of Toxicology (SOT) conference, further advancing preclinical research ...
Akeso, Inc. ("Akeso" or the "Company") announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collabor...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for...
Regeneron Pharmaceuticals, Inc. announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have p...
Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with...
© 2025 Biopharma Boardroom. All Rights Reserved.
